Ocular Therapeutix Missed Consensus Estimates
Tuesday, August 5, 2025 at 7:00 AM ET
Ocular Therapeutix (OCUL) reported a loss of $0.39 per share on revenue of $13.46 million for the second quarter ended June 2025. The consensus estimate was a loss of $0.35 per share on revenue of $13.55 million. The company missed consensus estimates by 11.43% while revenue fell 18.14% compared to the same quarter a year ago.
Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.39
Earnings Whisper®
-
Consensus Estimate
$-0.35
Earnings Surprise
Earnings Growth
Reported Revenue
$13.46 Mil
Revenue Estimate
$13.55 Mil
Revenue Surprise
Revenue Growth